Neopterin: A Promising Candidate Biomarker for Severe COVID-19
Wasihun Hailemichael*, Mulugeta Kiros, Yibeltal Akelew, Sissay Getu, Henok AndualemImmunology and Molecular Biology, Department of Medical laboratory science, Debre Tabor University, EthiopiaCitation:
Hailemichael W, Kiros M, Akelew Y, Getu S, Anudualem H (2021) Neopterin: A Promising Candidate Biomarker for Severe COVID-19. SciTech Central COVID-19.
Received: February 08, 2021 Accepted: February 09, 2021 Published: February 09, 2021
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread across the world since its first emergence in China in late 2019. It is a major public health concern with no effective treatments. The immunopathology of SARS-CoV-2 is associated with an excessive inflammatory response. Macrophage activation syndrome (MAS) is also associated with the severity of the disease in SARS-CoV-2-infected patients. Neopterin is a macrophage activation marker produced by monocytes and macrophages upon activation by interferon-gamma (IFN-γ). Neopterin is a well-established marker in a variety of diseases, and recent evidence indicates that it could be helpful in early prediction of the severity of COVID-19 disease and serve as a prognostic marker. Here, we outline the role of macrophage activation syndrome in the pathogenesis of SARS-CoV-2 and suggest that neopterin could be used as a biomarker for progression of COVID-19.
Keywords: COVID-19, MAS, Neopterin, SARS-CoV-2